Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult subject and pediatric subjects (aged greater than or equal to two (2) years).~* Is referred for a contrast-enhanced MRI of the CNS based on the results of a previous imaging procedure.~* Female of childbearing potential patients must have effective contraception (contraceptive pill or intra-uterine device) or be surgically sterilized or post-menopausal (minimum 12 months amenorrhea), or have a documented negative urine pregnancy test within 24 hours prior to study MRI.~* Has been fully informed about the study, and has consented to participate.~Exclusion Criteria:~* Having acute or chronic grade IV or V renal insufficiency.~* Known class III/IV congestive heart failure.~* Suffering from long QT syndrome.~* Unstable health condition or circumstances (e.g. suffering from severe claustrophobia).~* Having any contraindications to MRI such as a pace-maker, magnetic material or any other conditions that would preclude proximity to a strong magnetic field.~* Known allergy to Gadolinium chelates.~* Having received any contrast agent within 3 days prior to study contrast administration, or is scheduled to receive any contrast agent within 24 hours after the study contrast administration.~* Pregnant, breast feeding, or planning to become pregnant during the trial.~* Previously participated in this trial.~* Having participated within 30 days in another clinical trial involving an investigational drug.~* Any condition which, based on the investigator's clinical judgement, would prevent the patient from completing all trial assessments and visits.~* Inability or unwillingness to cooperate with the requirements of this trial.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dotarem (gadoterate meglumine ) (Type: EXPERIMENTAL): Dotarem and Magnevist were randomised as 2:1 ratio for adult patients.
- Magnevist (gadopentetate dimeglumine) (Type: ACTIVE_COMPARATOR): Dotarem and Magnevist were randomised as 2:1 ratio
- Dotarem 2 (gadoterate meglumine ) (Type: EXPERIMENTAL): Pediatric patients were assigned to Dotarem group only.

Based on this trial design, predict the completion outcome and termination type (if applicable).